INmune Bio Announces New Preclinical Data for INB03
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 16 2026
0mins
INmune Bio announces new preclinical data for INB03. The data will be presented at the American Association for Cancer Research, AACR, Annual Meeting 2026 in San Diego on April 17-22. Key Scientific Findings: Overcoming Resistance in Vitro: The combination of INB03 with either lapatinib or tucatinib produced statistically superior inhibition of cell proliferation and migration in both HER2+ JIMT-1 and brain-metastatic JIMT-1 Br3-luc cell lines compared to TKIs alone. Enhanced Tumor Control In Vivo: In female nude mice bearing JIMT-1 or JIMT-1 Br3-luc tumors, INB03 + TKI combinations markedly slowed tumor growth compared to TKIs alone. Reduction of Metastatic Spread: The addition of INB03 significantly reduced the incidence of metastases to brain, lung, and liver. Notably, it further enhanced tucatinib's effect on lung metastases. Mechanism of Action: These results support prior research showing that selective sTNF neutralization with INB03 down-regulates MUC4, a protein that shields the HER2 molecule and prevents therapies from binding effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INMB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INMB
Wall Street analysts forecast INMB stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.440
Low
8.00
Averages
8.00
High
8.00
Current: 1.440
Low
8.00
Averages
8.00
High
8.00
About INMB
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
- Clinical Advancement: GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 dosing initiated on May 14, 2026, marking a significant milestone in NK cell therapy that is expected to enhance its market competitiveness.
- Innovative Platform: The company's second-generation TriKE platform is described as 10-40 times more potent than the first generation, focusing on activating NK cells through nanobody technology, thereby improving therapeutic efficacy and reducing side effects, further solidifying its position in immuno-oncology.
- Funding Influx: Cumulative funding into NK-focused biotech has exceeded $4.2 billion from 2020 to 2026, indicating strong investment enthusiasm and market potential, with GT Biopharma positioned to benefit from this trend as a key player.
- Market Outlook: North America is expected to capture 44% of the global NK cell therapy market by 2026, and GT Biopharma's clinical trials and financial status provide a solid foundation for growth in this rapidly evolving market.
See More
INmune Bio Receives FDA Fast Track Designation for XPro™ in Alzheimer's Treatment
- FDA Fast Track Designation: INmune Bio's XPro™ (pegipanermin) has received Fast Track designation from the FDA for treating early Alzheimer's disease, marking a transformative milestone that underscores the company's innovative potential in addressing neuroinflammation and is expected to accelerate clinical development.
- Market Demand Response: According to the Alzheimer's Association, by 2026, approximately 7.4 million Americans aged 65 and older will be living with Alzheimer's dementia, alongside an additional 15 million experiencing mild cognitive impairment, indicating a significant and growing market need that XPro™ aims to address.
- Clinical Trial Design: The Phase 2b/3 registrational trial for XPro™ will target patients with early Alzheimer's disease who have biomarkers of inflammation, utilizing an adaptive trial design intended to enhance the efficiency of clinical studies and expedite drug approval.
- Innovative Treatment Mechanism: XPro™ selectively neutralizes soluble tumor necrosis factor (sTNF) to reduce neuroinflammation while preserving immune functions, offering a novel therapeutic option for Alzheimer's patients that could potentially alter the disease's progression.
See More
INmune Bio Reports Q1 2026 Earnings Beat Expectations
- Earnings Beat: INmune Bio reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.04, indicating an improvement in financial performance despite remaining in a loss position.
- Significant Loss Reduction: For the quarter ended March 31, 2026, the net loss attributable to common stockholders was approximately $5.4 million, a substantial decrease from about $9.7 million in the same quarter of 2025, reflecting progress in cost control and operational efficiency.
- R&D Spending Decline: Research and development expenses totaled approximately $3.6 million for Q1 2026, down from approximately $7.6 million in Q1 2025, indicating a strategic adjustment in R&D investment that may impact future product development timelines.
- Stable Cash Reserves: As of the end of the reporting period, INmune Bio had cash and equivalents of $21.36 million, ensuring the company has financial flexibility for future operations and R&D activities.
See More
INmune Bio Reports $45.9M Loss in 2025 Earnings
- Increased Financial Loss: INmune Bio reported a net loss of approximately $45.9 million for the year ended December 31, 2025, up from $42.1 million in 2024, indicating ongoing challenges in R&D and market promotion that may affect investor confidence.
- Decline in R&D Expenses: Research and development expenses for 2025 were approximately $20.7 million, significantly down from $33.2 million in 2024, suggesting a reduction in spending on the Alzheimer's trial, which could impact funding priorities for future projects.
- Intangible Asset Impairment: The company recorded a full impairment of $16.5 million for its intangible assets in 2025 due to the Alzheimer's trial failing to meet clinical endpoints, which may negatively affect future financing and partnership opportunities.
- Cash Flow Position: As of December 31, 2025, INmune Bio had approximately $24.8 million in cash and cash equivalents, sufficient to fund operations through Q1 2027, but still needs to seek additional funding to support late-stage development projects.
See More
INmune Bio Reports Disappointing FY Results
- Financial Performance: INmune Bio reported a FY GAAP EPS of -$1.86, missing expectations by $0.11, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: Despite a 400% year-over-year revenue increase to $0.05 million, the figure fell short of market expectations by $0.01 million, reflecting difficulties in market expansion that could limit future cash inflows.
- Clinical Trial Progress: The discussion around INmune Bio's XPro1595 Phase II MINDFuL results and registrational strategy for Alzheimer's disease highlights the company's ongoing investment in R&D, although it has yet to translate into financial gains in the short term.
- Market Performance: INmune Bio is rated as lagging behind the market in Seeking Alpha's quant ratings, indicating investor concerns regarding its future growth potential, which may lead to downward pressure on its stock price.
See More
INmune Bio Reports Financial Results for FY 2025
- Financial Performance: INmune Bio reported a net loss of approximately $45.9 million for FY 2025, an increase from $42.1 million in FY 2024, indicating ongoing pressure from R&D and operational expenses that may impact future funding capabilities.
- R&D Progress: The CORDStrom™ platform is on track to submit a Marketing Authorization Application (MAA) to the UK’s MHRA by mid-summer 2026, followed by EMA and FDA submissions, marking a significant milestone in the commercialization process of a key product.
- Clinical Trial Results: XPro™ has made new advancements in Alzheimer's disease clinical trials, with the FDA approving its progression to an adaptive Phase 2b/3 registrational pathway, indicating a clearer strategic positioning in the precision medicine landscape.
- Capital Operations: In 2025, the company raised $27.5 million through the sale of 4,304,707 shares of common stock, with cash reserves expected to last through Q1 2027, reflecting a cautious and forward-looking approach to capital allocation.
See More
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
- Clinical Advancement: GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 dosing initiated on May 14, 2026, marking a significant milestone in NK cell therapy that is expected to enhance its market competitiveness.
- Innovative Platform: The company's second-generation TriKE platform is described as 10-40 times more potent than the first generation, focusing on activating NK cells through nanobody technology, thereby improving therapeutic efficacy and reducing side effects, further solidifying its position in immuno-oncology.
- Funding Influx: Cumulative funding into NK-focused biotech has exceeded $4.2 billion from 2020 to 2026, indicating strong investment enthusiasm and market potential, with GT Biopharma positioned to benefit from this trend as a key player.
- Market Outlook: North America is expected to capture 44% of the global NK cell therapy market by 2026, and GT Biopharma's clinical trials and financial status provide a solid foundation for growth in this rapidly evolving market.
See More
INmune Bio Receives FDA Fast Track Designation for XPro™ in Alzheimer's Treatment
- FDA Fast Track Designation: INmune Bio's XPro™ (pegipanermin) has received Fast Track designation from the FDA for treating early Alzheimer's disease, marking a transformative milestone that underscores the company's innovative potential in addressing neuroinflammation and is expected to accelerate clinical development.
- Market Demand Response: According to the Alzheimer's Association, by 2026, approximately 7.4 million Americans aged 65 and older will be living with Alzheimer's dementia, alongside an additional 15 million experiencing mild cognitive impairment, indicating a significant and growing market need that XPro™ aims to address.
- Clinical Trial Design: The Phase 2b/3 registrational trial for XPro™ will target patients with early Alzheimer's disease who have biomarkers of inflammation, utilizing an adaptive trial design intended to enhance the efficiency of clinical studies and expedite drug approval.
- Innovative Treatment Mechanism: XPro™ selectively neutralizes soluble tumor necrosis factor (sTNF) to reduce neuroinflammation while preserving immune functions, offering a novel therapeutic option for Alzheimer's patients that could potentially alter the disease's progression.
See More
INmune Bio Reports Q1 2026 Earnings Beat Expectations
- Earnings Beat: INmune Bio reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.04, indicating an improvement in financial performance despite remaining in a loss position.
- Significant Loss Reduction: For the quarter ended March 31, 2026, the net loss attributable to common stockholders was approximately $5.4 million, a substantial decrease from about $9.7 million in the same quarter of 2025, reflecting progress in cost control and operational efficiency.
- R&D Spending Decline: Research and development expenses totaled approximately $3.6 million for Q1 2026, down from approximately $7.6 million in Q1 2025, indicating a strategic adjustment in R&D investment that may impact future product development timelines.
- Stable Cash Reserves: As of the end of the reporting period, INmune Bio had cash and equivalents of $21.36 million, ensuring the company has financial flexibility for future operations and R&D activities.
See More
INmune Bio Reports $45.9M Loss in 2025 Earnings
- Increased Financial Loss: INmune Bio reported a net loss of approximately $45.9 million for the year ended December 31, 2025, up from $42.1 million in 2024, indicating ongoing challenges in R&D and market promotion that may affect investor confidence.
- Decline in R&D Expenses: Research and development expenses for 2025 were approximately $20.7 million, significantly down from $33.2 million in 2024, suggesting a reduction in spending on the Alzheimer's trial, which could impact funding priorities for future projects.
- Intangible Asset Impairment: The company recorded a full impairment of $16.5 million for its intangible assets in 2025 due to the Alzheimer's trial failing to meet clinical endpoints, which may negatively affect future financing and partnership opportunities.
- Cash Flow Position: As of December 31, 2025, INmune Bio had approximately $24.8 million in cash and cash equivalents, sufficient to fund operations through Q1 2027, but still needs to seek additional funding to support late-stage development projects.
See More
INmune Bio Reports Disappointing FY Results
- Financial Performance: INmune Bio reported a FY GAAP EPS of -$1.86, missing expectations by $0.11, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: Despite a 400% year-over-year revenue increase to $0.05 million, the figure fell short of market expectations by $0.01 million, reflecting difficulties in market expansion that could limit future cash inflows.
- Clinical Trial Progress: The discussion around INmune Bio's XPro1595 Phase II MINDFuL results and registrational strategy for Alzheimer's disease highlights the company's ongoing investment in R&D, although it has yet to translate into financial gains in the short term.
- Market Performance: INmune Bio is rated as lagging behind the market in Seeking Alpha's quant ratings, indicating investor concerns regarding its future growth potential, which may lead to downward pressure on its stock price.
See More
INmune Bio Reports Financial Results for FY 2025
- Financial Performance: INmune Bio reported a net loss of approximately $45.9 million for FY 2025, an increase from $42.1 million in FY 2024, indicating ongoing pressure from R&D and operational expenses that may impact future funding capabilities.
- R&D Progress: The CORDStrom™ platform is on track to submit a Marketing Authorization Application (MAA) to the UK’s MHRA by mid-summer 2026, followed by EMA and FDA submissions, marking a significant milestone in the commercialization process of a key product.
- Clinical Trial Results: XPro™ has made new advancements in Alzheimer's disease clinical trials, with the FDA approving its progression to an adaptive Phase 2b/3 registrational pathway, indicating a clearer strategic positioning in the precision medicine landscape.
- Capital Operations: In 2025, the company raised $27.5 million through the sale of 4,304,707 shares of common stock, with cash reserves expected to last through Q1 2027, reflecting a cautious and forward-looking approach to capital allocation.
See More
